## CURRICULUM VITAE FOR ACADEMIC PROMOTION

The Johns Hopkins University School of Medicine

September 27, 2020

Duvuru Geetha, M.D., M.R.C.P., (U.K.)

## DEMOGRAPHIC AND PERSONAL INFORMATION

## **Current Appointment**

2014-Present Associate Professor, Division of Nephrology, Department of Medicine, Johns Hopkins University

School of Medicine.

Associate Professor, Division of Rheumatology Department of Medicine, Johns Hopkins 2017-Present

University School of Medicine

#### **Personal Data**

Johns Hopkins Bayview Medical Center

Division of Renal Medicine 301 Building, Suite 2500 4940 Eastern Avenue Baltimore, MD21224 Telephone: 410-550-2820 Fax: 410-550-7950

E-mail: gduvura@jhmi.edu

## **Education and Training**

09/84-12/89	M.B., B.S., Madras Medical College, Madras, India
01/89-12/89	House Officer Government General Hospital, Madras, India
03/90-05/90	Senior House Officer, Hematology and Oncology, Government General Hospital, Madras, India
02/91-07/91	House Officer, Internal Medicine, Preston Hospital, North Shields, U.K.
09/91-12/91	Senior House Officer, General/Geriatric Medicine, North Tyneside Hospital, North Shields, U.K.
01/92-08/92	Senior House Officer, Renal and Chest Medicine, Freeman Hospital, Newcastle Upon Tyne, U.K.
09/92-04/93	Research Fellow, Nephrology, Freeman Hospital, Newcastle Upon Tyne, U.K.
06/93-06/96	Residency, Internal Medicine, York Hospital, York, PA
07/96-06/98	Fellowship, Nephrology, Johns Hopkins Bayview Medical Center, Johns Hopkins University

## **Professional Experience**

07/98-08/01	Instructor, Division of	f Nephrology, Departme	ent of Medicine, Johns	Hopkins University.
01/20 00/01	monacion, Division of	i i topin ologi, bepartine	in or incurence, boins	Tropiums Cim (Cisic),

Baltimore, Maryland

09/01-09/14 Assistant Professor, Division of Nephrology, Department of Medicine, Johns Hopkins University,

Baltimore, Maryland

Associate Professor, Division of Nephrology, Department of Medicine, Johns Hopkins University, 2014-Present

Baltimore, Maryland

#### **PUBLICATIONS**

## Original Research [OR]

- 1. Goodship T, Stoddart J, Martinek V, Geetha D, Brown A, Ward M, Kerr D, Owen J and Wilkinson R. Long term follow-up of patients presenting to adult nephrologists with Chronic Pyelonephritis and 'normal' renal function. QJM, 2000;93:799-80
- 2. Thomas A, Dropulic L, Rahman M, Geetha D. Ureteral Stents: A novel risk factor for polyomavirus nephropathy. Transplantation. Aug. 2007;84(3):433-436.

- 3. **Geetha** D, Haas M, Kraus E, Rabb H, Seo P. Renal Transplantation in Wegener's Granulomatosis compared to Microscopic Polyangiitis. *J Rheumatol* 2010;37(8):1705-8.
- 4. Stone J, Merkel P, Spiera R, Seo P, Langford C, Hoffman G, Kallenberg G, St. Clair E, Turkiewicz A, Tchao N, Webber L, Ding L, Sejismundo L, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen N, Fervenza F, **Geetha D**, Keogh K, Kissin E, Monach P, Peikert T, Stegeman C, Ytterberg S, Specks U. Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis. RAVE–ITN Research Group. N Engl J Med 2010;363(3):221-232. As sole nephrologist on this study team, I made a substantial contribution to the patient enrollment, acquisition of data for the work and to the critical revision of the manuscript for important intellectual content.
- 5. **Geetha D,** Eirin A, True K, Irazabal M, Specks U, Seo P, Nachman P, Fervenza P. Renal Transplantation in ANCA associated vasculitis: A Multi Center Experience. *Transplantation* 2011;91(12):1370-5. *Results from this study confirmed the lower risk of post-renal transplant vasculitis recurrence with current immunosuppressive regimens in patients with ANCA vasculitis*.
- 6. **Geetha D**, Sozio S, Ghanta M, Josephson M, Shapiro R, Dadhania D, Hariharan S. Results of Repeat Renal Transplantation after Graft Loss from BK Virus Nephropathy. *Transplantation* 2011;92 (7):781-6.
- 7. <u>Havill J</u>, Levine M Stuart, Kuperman M, Hellmann DB, **Geetha D**. Falling through the cracks of vasculitis classification. NDT Plus 2011;4(5):327-330.
- 8. **Geetha D**, <u>Parkhie S</u>, <u>Nadkarni G</u>, He C, Shafi T. Polyomavirus Associated Nephropathy: A comparison of 2 different strategies of immunosuppression reduction. Medicine (Baltimore) 2011;90(5):296-302.
- 9. **Geetha D**, Seo P, Ellis C, Kuperman M, Levine Stuart M. Persistent or new onset microscopic hematuria in small vessel vasculitis patients in remission: Findings on renal biopsy. *J. Rheumatol* 2012;39(7):1413-7.
- 10. Sharif A, Alachkar N, Bagnasco S, **Geetha D**, Gupta G, Womer K, Arend L, Racusen L, Montgomery R, E. Incidence and outcomes of BK virus allograft nephropathy among ABO- and HLA-incompatible kidney transplant recipients. *Clin J Am Soc Nephrol* 2012;7(8):1320-7.
- 11. <u>Raman G</u>, <u>Srivastava A</u>, **Geetha D**. Outcome of Renal Transplantation in Patients with both ANCA and anti-GBM antibodies. *Transplantation* 2012;94(5):e30-1.
- 12. <u>Srivastava A, Rao GK</u>, Segal PE, Shah M, **Geetha D**. Characteristics and outcome of crescentic glomerulonephritis in patients with both antineutrophil cytoplasmic antibody and anti-glomerular basement membrane antibody. *Clin Rheumatol* 2013;32(9):1317-22.
- 13. Miloslavsky E, Specks U, Merkel P, Seo P, Spiera R, Langford C, Hoffman G, Kallenberg C, St Clair E, Tchao N, Viviano L, Ding L, Sejismundo L, Mieras K, Ikle D, Jepson B, Mueller M, Brunetta P, Allen N, Fervenza F, **Geetha D**, Keogh K, Kissin E, Monach P, Peikert T, Stegeman C, Ytterberg S, Stone H; for the RAVE-ITN Research Group. Clinical outcomes of remission induction therapy for severe ANCA-Associated vasculitis. *Arthritis Rheum* 2013; 65(9):2441-9.
- 14. Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Fessler BJ, Ding L, Viviano L, Tchao NK, Phippard DJ, Asare AL, Lim N, Ikle D, Jepson B, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh K, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Mueller M, Sejismundo LP, Mieras K, Stone JH; RAVE-ITN Research Group. Efficacy of Remission Induction Regimens for ANCA-Associated Vasculitis. N Engl J Med 2013;369(5):417-27. As sole nephrologist on this study team, I made a substantial contribution to the patient enrollment, acquisition of data for the work and to the critical revision of the manuscript for important intellectual content.
- 15. <u>Ellis CL</u>, Manno RL, <u>Havill JP</u>, Racusen LC, **Geetha D.** Validation of the new Classification of Pauci-Immune Glomerulonephritis in a United States cohort and its Correlation with Renal Outcome. *BMC Nephrol* 2013;14(1):210. *This was the first study validating the classification of ANCA GN in US cohort*
- 16. <u>Murakami C</u>, <u>Manoharan P</u>, Carter-Monroe N, **Geetha D**. Rituximab for remission induction in recurrent ANCA associated glomerulonephritis post kidney transplant. *Transpl Int* 2013;26(12):1225-31.
- 17. **Geetha D**, Poulton CJ, Hu Y, Seo P, McGregor JG, Falk RJ, Hogan SL. Clinical Characteristics and Outcome of Pauci-immune glomerulonephritis in African Americans. *Semin Arthritis and Rheum* 2014; 43(6):778-83.
- 18. **Geetha D**, Levine SM, Manno RL, Valsamakis A, Ghazarian S, Seo P. BK Virus Replication in Patients with ANCA Associated Vasculitis. *Am J Nephrol* 2014;39(1):20-6.
- 19. Chen TK, <u>Murakami C</u>, Manno RL, **Geetha D**. Hematuria duration does not predict kidney function at 1 year in ANCA-associated glomerulonephritis. *Semin Arthritis Rheum* 2014; 44(2):198-201.
- 20. Miloslavsky EM, Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Tchao NK, Viviano L, Ding L, Ikle D, Villarreal M, Jepson B, Brunetta P, Allen NB, Fervenza FC, **Geetha**

- **D**, Keogh K, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Stone JH. Rituximab for the treatment of relapses in ANCA-associated vasculitis. *Arthritis Rheumatol* 2014; 66(11):3151-59.
- 21. **Geetha D**, Specks U, Stone JH, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Fessler BJ, Ding L, Tchao NK, Ikle D, Jepson B, Brunetta P, Fervenza FC. Rituximab for ANCA-Associated Vasculitis Immune Tolerance Network Research Group. Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis with Renal Involvement. *J Am Soc Nephrol* 2015;26(4):976-85. *As one of the two nephrologists in this landmark trial, I made a substantial contribution to the design of the post-hoc analysis, acquisition of data for the work and to the writing of the manuscript.*
- 22. <u>Timlin H, Lee SM</u>, Manno RL, Seo P, **Geetha D**. Rituximab for remission induction in elderly patients with ANCA-associated vasculitis. *Semin Arthritis Rheum* 2015;45(1):67-9. *First study which addressed the efficacy and safety of rituximab for remission vasculitis in elderly patients with ANCA associated vasculitis.*
- 23. **Geetha D**, Hruskova Z, Segelmark M, Hogan J, Morgan MD, Cavero T, Eriksson P, Seo P, Manno RL, Dale J, Harper L, Tesar V, Jayne DR. Rituximab for treatment of severe renal disease in ANCA associated vasculitis. *J Nephrol* 2016;29(2):195-201. *First and sole study which addressed the efficacy and safety of rituximab for remission vasculitis in ANCA associated vasculitis patients presenting with severe renal disease.*
- 24. <u>Shah S</u>, Hruskova Z, Segelmark M, Morgan MD, Hogan J, Lee SK, Dale J, Harper L, Tesar V, Jayne DR, **Geetha D**. Treatment of Severe Renal Disease in ANCA Positive and Negative Small Vessel Vasculitis with Rituximab. *Am J Nephrol* 2015;41(4-5):296-301.
- 25. Manno RL, Seo P, **Geetha D**. Older patients with ANCA-associated vasculitis and dialysis dependent renal failure: a retrospective study. *BMC Nephrol* 2015;16:88.
- 26. **Geetha D**, Lee SK, Srivastava AJ, Kraus ES, Wright SM. Clinical excellence in nephrology: Examples from the published literature. *BMC Nephrol* 2015;16:141. *This paper is a collection of reports in nephrology illustrates that the definition of clinical excellence set forth by the Miller Coulson Academy is highly applicable to physicians caring for individuals with kidney disease.*
- 27. <u>Shah S</u>, <u>Havill J</u>, Rahman MH, **Geetha D**. A historical study of American patients with anti-neutrophil cytoplasmic antibody negative pauci-immune glomerulonephritis. *Clin Rheumatol* 2016;35(4):953-60.
- 28. **Geetha D**, <u>Lee SM</u>, <u>Shah S</u>, Rahman HM. Relevance of ANCA positivity at the time of renal transplantation in ANCA associated vasculitis. *J Nephrol* 2017;30(1):147-153.
- 29. <u>Shah S</u>, Jaggi K, Greenberg K, **Geetha D**. Immunoglobulin levels and infection risk with rituximab induction for ANCA associated vasculitis. *Clin Kidney J* 2017;10(4):470-74.
- 30. <u>Timlin H, Liebowitz J, Jaggi K, **Geetha D.** Outcomes of hydralazine induced renal vasculitis. *E Jour Rheum* 2018;5:5-8.</u>
- 31. **Geetha D**, Sethi S, De Vriese AS, Specks U, Kallenberg CGM, Lim N, Spiera R, St Clair EW, Merkel PA, Seo P, Monach PA, Lepori N, Fessler BJ, Langford CA, Hoffman GS, Sharma R, Stone JH, Fervenza FC; RAVE-ITN Research Group. Interstitial Immunostaining and Renal Outcomes in Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis. *Am J Nephrol* 2017;46(3):231-238. *As one of the two nephrologists in this landmark trial, I made a substantial contribution to the design of the post-hoc analysis, acquisition of data for the work and to the writing of the manuscript.*
- 32. Weiner M, Bjørneklett R, Hrušková Z, Mackinnon B, Poulton CJ, Sindelar L, Mohammad AJ, Eriksson P, Gesualdo L, **Geetha D**, Crnogorac M, Jayne D, Hogan SL, Geddes C, Tesar V, Aasarød K, Segelmark M. Proteinase-3 and myeloperoxidase serotype in relation to demographic factors and geographic distribution in antineutrophil cytoplasmic antibody-associated glomerulonephritis. *Nephrol Dial Transplant* 2019:34(2):301-308.
- 33. Novick TK, Chen M, Scott J, Cortazar, FB, Ayoub I, Little, MA, Hruskova Z, Salama, AD, Pagnoux C, Geetha D. Patient Outcomes in Renal-Limited Antineutrophil Cytoplasmic Antibody Vasculitis with Inactive Histology. *Kidney Int Rep* 2018;3:671–676. *This is a multicenter study which reported outcomes on treatment of rare ANCA vasculitis phenotype*.
- 34. Gapud EJ, Manno R, Seo P, Hanouneh M, **Geetha D**. Long-term Clinical Course of Antineutrophil Cytoplasmic Antibody-associated Vasculitis Patients off Maintenance Therapy. *Cureus* 2018;10(3):e2372.
- 35. <u>Kant S</u>, Shah AA, Hummers LK, Wigley FM, **Geetha D**. ANCA-associated vasculitis in scleroderma: A renal perspective. *Clin Nephrol* 2018;90(6):413-418.
- 36. Menez S, Hruskova Z, Scott J, Cormican S, Chen M, Salama AD, Alasfar S, Little MA, Safrankova H, Honsova E, Tesar V, **Geetha D**. Predictors of Renal Outcomes in Sclerotic Class Anti-Neutrophil Cytoplasmic Antibody Glomerulonephritis. *Am J Nephrol* 2018;48(6):465-471.

- 37. <u>Katikeneni VS, Kant S,</u> Gapud EJ, Antiochos B, Manno RL, Phillips M, Seo P, **Geetha D**. Uncommon presentations in ANCA vasculitis: clinical characteristics and outcomes. *Clin Rheumatol* 2019;38(8):2195-2199.
- 38. Kronbichler A, Leierer J, Shin JI, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CGM, St Clair EW, Brunetta P, Fervenza FC, **Geetha D**, Keogh KA, Monach PA, Ytterberg SR, Mayer G, Specks U, Stone JH; RAVE—ITN Research Group. The Association of Pulmonary Haemorrhage, Positive PR3-ANCA and Urinary Red Blood Cell Casts with Venous Thromboembolism in ANCA-Associated Vasculitis Arthritis *Rheumatol* 2019;71(11):1888-93.
- 39. Goules A, **Geetha D**, Arend LJ, Baer AN. Renal involvement in primary Sjögren's syndrome: natural history and treatment outcome. *Clin Exp Rheumatol* 2019;37 Suppl 118(3):123-132.
- 40. <u>Timlin H</u>, Wu M, Crespo-Bosque M, **Geetha D**, Ingolia A, Haque U, Towns MC, Grader-Beck T. Clinical Characteristics of Hydralazine-induced Lupus. *Cureus* 2019;11(6):e4996.
- 41. <u>Kant S</u>, Habbach A, Gapud EJ, Manno RL, Gattu R, Seo P, **Geetha D**. Sequential Therapy for Remission Induction in Severe Antineutrophil Cytoplasmic Autoantibody-Associated Glomerulonephritis. *Am J Nephrol* 2019;50(5):386-91.
- 42. <u>Kant S</u>, Azar A, Gapud EJ, Antiochos B, Manno R, Seo P, Geetha D. Subcutaneous Immunoglobulin for Antibody Deficiency in Antineutrophil Cytoplasmic Antibody (ANCA)-associated Vasculitis. *Cureus* 2019;11(12): e6367.
- 43. <u>Bradley Isaacs</u>, Eric J. Gapud, Brendan Antiochos, Philip Seo and **Duvuru Geetha**. Venous thrombotic events in ANCA-associated vasculitis: Incidence and risk factors. Kidney360 March 2020, 10.34067/KID.0000572019; DOI: https://doi.org/10.34067/KID.0000572019
- 44. Morris AD, Elsayed ME, Ponnusamy A, Rowbottom A, Martin F, **Geetha D**, Dhaygude AP. Treatment Outcomes of Anti-Neutrophil Cytoplasmic Autoantibody-Associated Vasculitis in Patients Over Age 75 Years: A Meta-Analysis. Am J Nephrol. 2020 Mar 11:1-9. doi: 10.1159/000506532. [Epub ahead of print]
- 45. Sam Kant, Adam Morris, Srekar Ravi, Lauren Floyd, Eric Gapud, Brendan Antiochos, Ajay Dhaygude, <sup>2</sup>\ Phil Seo and **Duvuru Geetha.** The Impact of COVID-19 Pandemic on Patients with ANCA associated Vasculitis. Journal of Nephrology: 2020 (In press)

## **Review Articles [RA]**

- 1. **Geetha D**, Seo P. Renal transplantation in the ANCA associated vasculitides. *Am J Transplant* 2007;7(12) 2567-62.
- 2. Geetha D, Seo P. Advances in therapy for ANCA associated vasculitis. Curr Rheumatol Rep 2012; 14(6)509-15
- 3. Krajewski CM, **Geetha D**, Gomez-Lobo V. Contraceptive options for women with history of solid organ transplant. *Transplantation* 2013;95(10):1183-86.
- 4. **Geetha D**, Kallenberg C, Stone JH, Salama AD, Appel GB, Duna G, Brunetta P, Jayne D. Current therapy of granulomatosis with polyangiitis and microscopic polyangiitis: the role of rituximab. *Nephrol* 2014;28(1):17-27.
- 5. Hruskova Z, **Geetha D**, Tesar V. Renal transplantation in anti-neutrophil cytoplasmic antibody-associated vasculitis. *Nephrol Dial Transplant* 2015;30 Suppl 1:i159-63.
- 6. <u>Shah S.</u> **Geetha D**. Place in therapy of rituximab in the treatment of granulomatosis with polyangiitis and microscopic polyangiitis.Immunotargets Ther. 2015 Aug 7; 4:173-83
- 7. **Geetha D**, Jin Q, Scott J, Hruskova Z, Hanouneh M, Little MA, Tesar V, Seo P, Jayne DR, Pagnoux C. Comparisons of Guidelines and Recommendations on Managing ANCA-Associated Vasculitis. *Kidney Intl Rep* 2018;3(5):1039-49.
- 8. **Geetha D,** <u>Kant S.</u> Recommendations for kidney transplantation in patients with ANCA-associated vasculitis. *Expert Rev Clin Immunol* 2018;14(3):235-40.
- 9. **Geetha D**, Jefferson JA. ANCA-associated vasculitis: Core Curriculum 2020. *Am J Kidney Dis* 2019;75(1):124-137. *Was rated as Global Top 10 most read papers through Read by QxMD for the last month*
- 10. Hruskova Z, Tesar V, **Geetha D**. Renal Transplantation in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Current Perspectives. Kidney Blood Press Res. 2020;45(2):157-165. doi: 10.1159/000505660. Epub 2020 Feb 19. Review.

11.Gapud EJ, Kronbichler A, Gauckler P, **Geetha D**. Immunotherapy for ANCA-associated vasculitis during the COVID-19 pandemic. Eur J Rheumatol. 2020 Jul 21. doi: 10.5152/eurjrheum.2020.2067

## Case Reports [CR]

- 1. **Geetha D**, Zachary J, Baldado H, Kronz J, Kraus E. Pure red cell aplasia induced by Parvovirus B19 in solid organ transplant recipients: A case report and review of the literature. *Clin Transplantation* 2000;14:586-91.
- 2. **Geetha D**, Tong B, Racussen L, Markowitz J, Westra W. Bladder carcinoma in a transplant recipient: Evidence to implicate the BK human polyomavirus as a causal transforming agent. *Transplantation* 2002;73(12):1933-36.
- 3. **Geetha D**, Seo P, Specks U, Fervenza F. Successful induction of remission with rituximab for relapse of ANCA associated vasculitis post kidney Transplant: Report of 2 cases. *Am J Transplant* 2007;7(12):2821-25.
- 4. <u>Sharma P, Kuperman M, Racusen L, **Geetha D**. Fibrillary Glomerulonephritis Presenting as Rapidly Progressive Glomerulonephritis. *AJKD* 2012;60(1):157-59.</u>
- 5. <u>Duggal T</u>, Segal PE, <u>Shah M</u>, Manoharan P, **Geetha D.** ANCA associated vasculitis associated with influenza vaccination. Nephrology Grand Rounds. *Am J Nephrol* 2013;38(2):174-78.
- 6. <u>Lee SM</u>, **Geetha D**. Dapsone induced hemolysis in a patient with ANCA associated glomerulonephritis and normal G6PD level and implications for clinical practice: case report and review of the literature. *Springerplus* 2015;23(4):29.
- 7. Shah S, Sethi S, Arend L, Geetha D. Crystal storing histiocytosis: Nephrology Image. Kidney Int 2016;89(2):507.
- 8. <u>Hanouneh H</u>, Damera P, Fetrat M, **Geetha D**. An unusual complication of peritoneal dialysis. *Cleve Clin J Med* 2018;85(5):352-54
- 9. Dein EJ, Crespo-Bosque M, Timlin H, **Geetha D**. Double-positive with positive anti-glomerular basement membrane antibody and ANCA-positive disease in a patient with dermatomyositis. *BMJ Case Rep* 2018;24:2018.
- 10. Dein E, Manno R, Syed A, Douglas H, **Geetha D**, Timlin H. Ranolazine-induced Elevation of Creatinine Kinase in the Absence of Statin Usage. *Cureus* 2018;10(6):e2832.
- 11. <u>Jin Q</u>, <u>Kant S</u>, Alhariri J, **Geetha D.** Levamisole adulterated cocaine associated ANCA vasculitis: review of literature and update on pathogenesis. *Community Hosp Intern Med Perspect* 2018;8(6):339-344.

## Letters, Correspondence [LT]

- 1. **Geetha, D.** Omeprazole induced acute interstitial nephritis. Am J of Gastroenterol 1999; 94(11):3375-76.
- 2. **Geetha, D**. Ureteral stent placement and BK virus allograft nephropathy in renal transplant recipients. *Transplantation* 2008; 85(4):658-59.
- 3. Morris A, **Geetha D**. PEXIVAS challenges current ANCA-associated vasculitis therapy.Nat Rev Nephrol. 2020 Mar 13. doi: 10.1038/s41581-020-0269-6. [Epub ahead of print]

## **Book Chapters, Monographs [BC]**

- 1. **Geetha D**, Stone J. Henoch-Schonlein Purpura 2<sup>nd</sup> edition of Current Diagnosis & Treatment in Rheumatology. McGraw-Hill Professional; 2007.
- 2. **Geetha D**, Stone J. Mixed Cryoglobulinemia 2<sup>nd</sup> edition of Current Diagnosis & Treatment in Rheumatology. McGraw-Hill Professional; 2007.
- 3. **Geetha D**, Stone J. Microscopic Polyangiitis 2<sup>nd</sup> edition of Current Diagnosis & Treatment in Rheumatology. McGraw-Hill Professional; 2007.
- 4. **Geetha D**. "Post streptococcal glomerulonephritis." Chapter published on line in emedicine series of online textbooks. 2010.
- 5. **Geetha D**, Seo P. Life Threatening Emergencies in ANCA associated vasculitis. Autoimmune Diseases: Complex and acute situations. Springer, London; 2011. Page 101-118.
- 6. Monroy-Trujillo J, **Geetha D**. Kidney Protection: Strategies for Renal Preservation. Chapter 33, Systemic Inflammatory Diseases and the Kidney. Oxford University Press, March 2019.

## **Editorials [ED]:**

1. Brix SR, **Geetha D.** Keeping Up with the Times: Prognostic Tools in ANCA-Associated Glomerulonephritis Clin J Am Soc Nephrol. 2020 Jul 28:CJN.09600620. doi: 10.2215/CJN.09600620. Online ahead of print.

#### Media Releases

1. August 29, 2018 CLOSLER interview:

https://closler.org/passion-in-the-medical-profession/interview-with-dr-geetha-a-closler-look

- 2. October 9, 2019 Commentary on ANCA associated vasculitis mortality falling slightly: <a href="https://www.the-rheumatologist.org/article/mortality-from-antineutrophil-cytoplasmic-autoantibody-associated-vasculitis-falling-slightly/">https://www.the-rheumatologist.org/article/mortality-from-antineutrophil-cytoplasmic-autoantibody-associated-vasculitis-falling-slightly/</a>
- 3. November 19, 2019 Nephrology View Point by Dr. Richard Glassock: https://www.karger.com/Blog/Nephrology-Viewpoints/remission-induction-in-anca-vasculitis
- 4. April 29, 2020 Nephrology View Point by Dr. Richard Glassock: <a href="https://www.karger.com/Blog/Nephrology-Viewpoints/anca-associated-vasculitis-in-the-elderly">https://www.karger.com/Blog/Nephrology-Viewpoints/anca-associated-vasculitis-in-the-elderly</a>
- 5. April 30, 2020. Kidney 360 Podcast on "Venous thrombotic events in ANCA associated vasculitis: Incidence and risk factors". <a href="https://podcasts.apple.com/us/podcast/article-summary-by-duvuru-geetha-and-andreas-kronbichler/id1497209592?i=1000473187550">https://podcasts.apple.com/us/podcast/article-summary-by-duvuru-geetha-and-andreas-kronbichler/id1497209592?i=1000473187550</a>

## **FUNDING**

### **Research Extramural Funding**

#### **Current Grants**

04/17-Present Avocapan development in vasculitis to obtain corticosteroid elimination and therapeutic

efficacy: international multi-center study

Sponsor: ChemoCentryx Site PI (D Geetha): 10% effort

04/19-Present A Randomized, Double-Blind, Placebo-Controlled, Multicentre, Parallel-Group Phase II

Study to Investigate the Safety and Efficacy of two different dose regimens of IFX-1 as add-

on to Standard of Care in subjects with Granulomatosis with Polyangiitis (GPA) and

Microscopic Polyangiitis (MPA)

Sponsor: InflaRx

Site PI (D Geetha): 10% effort

## **Research Intramural Funding**

## **Current Grants**

01/18-Present Assessment of complement activation in anti-neutrophil cytoplasmic antibody associated

glomerulonephritis

Jerome L. Greene Foundation Discovery Fund

\$45,000.00

PI: Duvuru Geetha, MD: 10% effort

04/19-Present Characterization of granzyme B producing auto-reactive T cells in renal anti-neutrophil

cytoplasmic antibody associated glomerulonephritis

Cupid Foundation Discovery Fund

\$50,000.00

PI: Duvuru Geetha, MD: 5% effort

**Pending Grants** None

**Previous Grants** 

09/92-04/93 Chronic Pyelonephritis

A Northern Counties Kidney Research Fund in U.K

PI: Duvuru Geetha, MD

Role: Research Fellow working on natural history of Chronic Pyelonephritis

07/98-06/99 Water and solute transport characteristics of the rat urinary bladder

National Kidney Foundation Grant: Maryland Mini-Grant

PI: David Spector, MD Role: Co-Investigator

07/99-06/00 Water and solute transport characteristics of the rat urinary bladder.

National Kidney Foundation Grant: Maryland Mini-Grant

PI: David Spector, MD Role: Co-Investigator

07/04-06/05 Pathogenesis of Polyomavirus Nephropathy: the Role of BKV Genotypes and Co

Infection with JC Virus and SV 40 Virus.

National Kidney Foundation Grant: Maryland Mini-Grant

\$10,000.00

PI: Duvuru Geetha, MD

07/11-06/12 Prevalence of BK virus replication in patients with ANCA associated Vasculitis: A

prospective study

Stabler Foundation Grant

\$25,000.00

PI: Duvuru Geetha, MD

12/11-01/14 Clinical Course and Clinical Outcomes among Subjects with ANCA Associated Vasculitis

and Renal Disease in the RAVE Cohort: Ancillary Study to RAVE.

Genentech

Site PI: 5% effort

07/12–06/13 Establishing a model comprehensive database to facilitate translational research in systemic

Vasculitis: A Prospective Database

Stabler Foundation Grant

\$30,000.00

PI: Duvuru Geetha, MD

04/15-06/16 Prospective study of urinary cell mRNA expression profiles in ANCA associated

Glomerulonephritis Stabler Foundation Grant

\$25,000.00

PI: Duvuru Geetha, MD

05/2019 to date Characterization of granzyme B producing auto-reactive T cells in renal ANCA associated

vasculitis

Cupid Discovery Award

\$50,000.00

PI: Duvuru Geetha, MD

#### **CLINICAL ACTIVITIES**

#### **Clinical Focus**

My clinical focus is on renal vasculitis. I joined the Johns Hopkins Vasculitis Center in 2005 where I currently serve as the Associate director of the Vasculitis Center. I established a renal clinic at the vasculitis center to focus on renal vasculitis in 2005. My role has been to help with early diagnosis of renal involvement by vasculitis and provide timely treatment. During this period, I evaluated many vasculitis patients who have lost their kidneys to vasculitis for candidacy for renal transplant and improved their access to transplantation. My focused care of these patients in the vasculitis center has increased the transplants exponentially at out center and I have described the outcome of ANCA associated vasculitis patients who underwent renal transplantation for their end stage renal disease in both the Johns Hopkins and national cohorts. In addition, I reported on the use of a novel agent, rituximab, as the appropriate treatment in recurrent ANCA associated glomerulonephritides in post-renal transplant patients. I was recruited to be one of two nephrologists in the world to participate in the RAVE Research Group, an international group of rheumatologists and nephrologists who study vasculitis. Through this collaborative effort, two major papers were published in the New England Journal of Medicine on the management of renal vasculitis. These two papers and a third, which was published in the Arthritis and Rheumatism have changed the standard of care internationally in the management of these disorders. We published the use of rituximab for severe renal vasculitis by conducting a multicenter International study. Iam currently the site PI for ADVOCATE (Avacopan Development in Vasculitis to Obtain Corticosteroid Elimination and Therapeutic Efficacy) trial in ANCA vasculitis using C5a receptor inhibition and a phase 2 study of a monoclonal antibody to C5a for remission induction in ANXA vasculitis.

#### Certification

## Medical, other state/government licensure

1996-1998 Pennsylvania Medical License (MD 058996L)

1998-Present Maryland Medical License (D 53421) 1998-Present CDS license, State of Maryland

1998-Present DEA license

## Boards, Other Specialty Certification

1992 Education Commission for Foreign Medical Graduates (ECFMG)

Member of Royal College of Physicians (UK), 1992

1993 Federal Licensing Examination (FLEX)

1995-Present Diplomate, American Board of Internal Medicine, Recertified 2005 1998 Specialist in Clinical Hypertension, American Society of Hypertension

1998-Present Diplomate, American Board of Internal Medicine, Nephrology, Recertified 2018

## Clinical (Service) Responsibilities

07/98-06/05 Johns Hopkins Bayview Renal Consult Service: 6-8-weeks

Franklin Square Hospital Renal Consult Service: 24-26 weeks Nephrology Outpatient Clinic: Two half-day sessions per week

07/98-06/16 Davita JB Zachary Triad Dialysis: I follow both hemodialysis and peritoneal dialysis patients at

this location and have hemodialysis clinics and peritoneal dialysis clinics (59 dialysis patients at

this location).

07/01-06/16 Davita White Square Dialysis: I follow both hemodialysis and peritoneal dialysis patients at this

location and have hemodialysis clinics and peritoneal dialysis Clinics (12 patients at this location)

07/05-06/10 Johns Hopkins Bayview Renal Consult Service: 6-8 weeks

Franklin Square Hospital Renal Consult service: 12-14 weeks Nephrology Outpatient Clinic: Two half-day sessions per week

Vasculitis Clinic: One half-day session per week

07/10-Present Johns Hopkins Bayview Renal Consult Service: 8-10 weeks

Johns Hopkins Bayview Renal Clinic and Care Center Service: 6-8 weeks

Nephrology Outpatient Clinic: One half-day session per week

Vasculitis Clinic: One 2-hour session per week

Peritoneal Dialysis Clinic: Four half-day sessions per month Home Hemodialysis Clinic: One half-day session per month

07/16-Present

Fresenius Kidney Care Fleet Street: I follow in-center hemodialysis, home hemodialysis and peritoneal dialysis patients at this location and have hemodialysis clinics and peritoneal dialysis

Clinics (50 in-center and 14 home dialysis patients)

### **Clinical Productivity**

Consistently exceeded target RUV's for the past 3 years and generated 8519 RUV's exceeding the target RVU of 7519 for FY19 year.

Clinical Draw from outside local/regional area: more than 90 percent of my patients travel beyond a 10 mile radius and over 30% of my patients come from out of state or out of country. The states represented include: Virginia, Washington DC, West Virginia, North Carolina, South Carolina, Tennessee, Texas, Florida, Kentucky, Indianapolis, Pennsylvania, Delaware, New Jersey, New York, Connecticut, New Hampshire, and Los Angeles Countries represented include: China, India, Pakistan, Abudabi, Greece, and Puerto Rico

Membership in or examiner for specialty board: None

## Clinical Program Building/Leadership

2005-Present

Renal clinic at Johns Hopkins Vasculitis Center: I am the lead nephrologist at the nationally recognized Johns Hopkins Vasculitis Center since 2005. I have established a weekly renal clinic at the Vasculitis Center and see patients throughout the United States, Europe and Middle East. I was a co-investigator in the landmark RAVE trial that led to the FDA approval of rituximab for treatment of ANCA vasculitis and was responsible for recruitment and follow up of renal patients in this trial. I am the Principal Investigator for the vasculitis database established in 2013. I am currently the site PI for ADVOCATE (Avacopan Development in Vasculitis to Obtain Corticosteroid Elimination and Therapeutic Efficacy) trial in ANCA vasculitis using C5a receptor inhibition and a phase 2 study of a monoclonal antibody to C5a for remission induction in ANCA vasculitis.

Clinical Demonstration Activities to external audience, on or off campus: None

Development of nationally/internationally recognized clinical standard of care: None

#### **EDUCATIONAL ACTIVITIES**

#### **Educational Focus**

I am a clinical nephrologist and my area of expertise is in renal vasculitis. My clinical practice includes patients with renal vasculitis, patients with chronic kidney disease, end stage renal disease patients and kidney transplant recipients. My educational focus is on renal vasculitis, peritoneal dialysis and renal transplant. I have developed a teaching curriculum for vasculitis patients to help train nephrology fellows on evaluation and management of vasculitis patients. I am the sole provider for peritoneal dialysis patients at Fleet Street dialysis unit and nephrology fellows rotate in this clinic during their second year. My role is to supervise and educate nephrology fellows on peritoneal dialysis prescription writing and management of complications of peritoneal dialysis. I have focused on renal transplant patient management since the beginning of my career and have contributed to teaching fellows on management of immunosuppression and complications of immunosuppression post renal transplant.

# Teaching:

## Classroom Instruction

Classroom Instruc	ction
JHMI/Regional	
1998-Present	Didactic Conference Faculty, Johns Hopkins Bayview Medical Center.
2001-2010	Fellowship Didactic Dialysis and Transplant Conference Coordinator, Johns Hopkins Bayview
	Medical Center, Division of Nephrology.
2004	Evaluation of acute renal failure in a transplant patient. Johns Hopkins Bayview Medical Center,
	Resident Noon Conference.
2005	Approach to Glomerular Disease. Franklin Square Hospital, Resident Noon Conference.
7/2006	Lectures on renal handling of potassium. Johns Hopkins Bayview Medical Center Nephrology
	Fellowship Program.
7/2007	Lectures on renal handling of phosphorus. Johns Hopkins Bayview Medical Center, Nephrology
	Fellowship Program.
8/2008	Lectures on renal handling of potassium. Johns Hopkins Bayview Medical Center, Nephrology
	Fellowship Program.
2008	HIV and Chronic Kidney Disease. Franklin Square Hospital, Resident Noon Conference.
2008	HIV and Chronic Kidney Disease. Johns Hopkins Bayview Medical Center, Resident Noon
	Conference.
2009	Approach to urinalysis. Franklin Square Hospital, Resident Noon Conference
2010	Primary care for the renal transplant recipient. Johns Hopkins Bayview Medical Center, Resident
	Noon Conference.
2010-Present	Genes to Society, Renal Course Faculty, Johns Hopkins University School of Medicine
2011	Renal manifestations of rheumatologic diseases. Rheumatology Fellows Core Curriculum, Johns
	Hopkins Bayview Medical Center.
2011	Renal manifestations of rheumatologic diseases 101: Rheumatology fellows core curriculum,
	Johns Hopkins Bayview Medical Center.
2012	Renal emergencies in rheumatologic diseases: Rheumatology fellows crash course
	Johns Hopkins Bayview Medical Center.
2012	Renal manifestations of rheumatologic diseases 101: Rheumatology fellows core curriculum,
	Johns Hopkins Bayview Medical Center.
2013	Renal Pathology 101: Rheumatology fellows core curriculum. Johns Hopkins Bayview Medical
	Center.
2013	Renal manifestations of rheumatologic diseases 101: Rheumatology fellows core curriculum,
	Johns Hopkins Bayview Medical Center
2014	Renal Pathology 101: Rheumatology fellows core curriculum. Johns Hopkins Bayview Medical
	Center.
2014	Renal manifestations of rheumatologic diseases. Rheumatology Fellows Core Curriculum, Johns
	Hopkins Bayview Medical Center
2014	Management of ANCA associated vasculitis Part 1. Renal fellows' noon conference
2015	Renal manifestations of rheumatologic diseases 101. Rheumatology Fellows Core Curriculum,
	Johns Hopkins Bayview Medical Center
2015	Management of ANCA associated vasculitis Part 2. Renal fellows' noon conference
2016	ANCA associated vasculitis: update. Johns Hopkins Bayview Medical Center, Resident Noon
	Conference.
2016	Renal manifestations of rheumatologic diseases 101: Rheumatology fellows core curriculum,
	Johns Hopkins Bayview Medical Center
2017	Why and what should a rheumatologist know about renal disease: Rheumatology fellows' core
_01,	curriculum, Johns Hopkins Bayview Medical Center
2018	Management of ANCA associated vasculitis. Renal fellows' noon conference
2019	Renal manifestations of rheumatologic diseases 101. Rheumatology Fellows Core Curriculum,
	Johns Hopkins Bayview Medical Center
2020	ANCA associated vasculitis in 2020. Renal fellows noon conference
2020	The Contraction of the Contracti

2020 Approach to acute kidney injury from glomerular disease: Internal Medicine Residents noon

conference

National:

2018 Management of ANCA associated vasculitis: Glomerular disease update: ASN Kidney Week

Early Program, San Diego, CA

Vasculitis and renal transplantation. Cutting Edge Vasculitis. 19<sup>th</sup> International Vasculitis and

ANCA workshop, Philadelphia, April 2019

2019 Management of ANCA associated vasculitis: Glomerular disease update: ASN Kidney Week

Early Program, Washington DC

2020 Targeting complement in patients with ANCA associated vasculitis, ASN 2020 Kidney Week

International:

ANCA associated vasculitis: Advances in induction therapy: Renal Grand rounds and meet the

professor: Stanley Medical College, Chennai, India. 1/10/18

2020 "(How) should we alter acute management of AAV in the COVID-19 era?" UKIVAS and Royal

Society of Medicine virtual meeting: scheduled date November 11th to 12th 2020

#### Clinical Instruction

JHMI/Regional

1998-Present Attending Physician, Nephrology Consultations, Johns Hopkins Bayview Medical Center

1998-2010 Attending Physician, Nephrology Consultations, Franklin Square Hospital

Preceptor, Nephrology Fellowship Outpatient Clinic, Johns Hopkins Bayview Medical Center
Approach to disorders of serum potassium. Monthly resident lectures, Franklin Square Hospital
Johns Hopkins Vasculitis Center Experience for 2nd year fellows. Nephrology fellows rotate

through this Clinic for 6-8 weeks in the 2nd year of fellowship.

National: None International: None

#### CME Instruction

2011

2013

JHMI/Regional	
2000	"Renophobia Relief" CME course. "Drugs and Kidney: Practical Bedside Pharmacology,
	Baltimore Maryland
2001	Polyomavirus Nephropathy. Grand Rounds. Johns Hopkins Bayview . Baltimore, MD
2002	Acute interstitial nephritis. Grand Rounds. Johns Hopkins Bayview. Baltimore, MD
2003	"HIV and ESRD: ESRD Conference
	Division of Nephrology, Johns Hopkins Bayview Medical Center, Baltimore, Maryland
2004	"ABC of Renal Transplantation" BK virus infection in Kidney Transplant Patients, Baltimore, MD
2004	"Treatment of Membranous Nephropathy": Topics in Nephrology
	Division of Nephrology, Johns Hopkins Bayview Medical Center, Baltimore, Maryland
2006	Polyomavirus nephropathy in renal transplant recipients. Renal Grand Rounds. Johns Hopkins
	University, School of Medicine. Baltimore, Maryland.
2006	"Proteomics in Nephrology": Topics in Nephrology
	Division of Nephrology, Johns Hopkins Bayview Medical Center, Baltimore, Maryland
2007	Treatment approaches to ANCA associated vasculitis. Renal Grand Rounds. Johns Hopkins
	University School of Medicine. Baltimore, Maryland.
2011	What should a Rheumatologist know about renal vasculitis? Rheumatology Grand Rounds. Johns

Hospital, Johns Hopkins University School of Medicine, Baltimore, Maryland

What should a Nephrologist know about ANCA vasculitis? Renal Grand Rounds. Johns Hopkins

Advances in therapy of ANCA associated renal disease: Medical Grand Rounds: Johns Hopkins

Hopkins University School of Medicine. Baltimore, Maryland.

University School of Medicine. Baltimore, Maryland

#### CONFIDENTIAL

2016	ANCA associated vasculitis: update on diagnosis and management. Medical Grand Rounds: St.
2016	Agnes Hospital, Baltimore, Maryland Approach to relapse prevention in ANCA associated vasculitis. Renal Rounds: University of Maryland Medical Center, Baltimore, Maryland
2017	ANCA associated vasculitis: update on diagnosis and management. Medical Grand Rounds: Greater Baltimore Medical Center, Baltimore, Maryland
National	
2012	Novel Therapies for Vasculitis Associated Renal Disease: National Kidney Foundation Spring Clinical Meeting 2013, Orlando, FL
2017	Retiform Purpura and Pauci-immune Glomerulonephritis: Clues to the Culprit. ASN Kidney Week 2017, New Orleans LA
2018	Management of ANCA associated vasculitis: Glomerular disease update: ASN Kidney Week Early Program, San Diego, CA
2018	Tailoring maintenance therapy in ANCA vasculitis. ASN Kidney Week 2018, San Diego CA
2019	Vasculitis and renal transplantation. Cutting Edge Vasculitis. 19 <sup>th</sup> International Vasculitis and ANCA workshop, Philadelphia, April 2019
2019	Management of ANCA associated vasculitis: Glomerular disease update: ASN Kidney Week Early Program, Washington DC
2020	ANCA and anti-GBM Disease in 2020-Some Old and Some New: An update in Glomerular diseases, 2020. North Shore University Hospital, New York. Scheduled May 2 <sup>nd</sup> 2020
2020	Targeting complement in patients with ANCA associated vasculitis, ASN 2020 Kidney Week
International	
2020	"(How) should we alter acute management of AAV in the COVID-19 era?" UKIVAS and Royal Society of Medicine virtual meeting: scheduled date November 11 <sup>th</sup> to 12 <sup>th</sup> 2020
*** 1.1 (6 :	

## Workshops/Seminars

TTTT	# T			1
111	/I I .	$\mu$	1011	าทกไ
JHN	/11/	1/0	2210	шаі

Vasculitis Foundation Patient Symposium speaker, Vasculitis Foundation, Baltimore, Maryland

02/2017 Vasculitis Foundation Patient Symposium: speaker, Bethesda, Maryland

#### National

2013 Vasculitis Foundation Patient Symposium, speaker/ panelist, Vasculitis Foundation, Philadelphia,

 $\mathbf{P}\mathbf{A}$ 

2017 International Vasculitis Symposium, speaker and panelist, Chicago, Illinois

2019 Cutting Edge Vasculitis. 19th International Vasculitis and ANCA workshop, Philadelphia, April

2019. Faculty panel "Question & Answer Session on Renal Vasculitis"

2019 Standardized outcomes in Nephrology-Glomerular disease workshop faculty participant,

Washington DC

International None

## Mentoring

## **Pre-doctoral Advisees / Mentees**

2011	Amar Srivastava, Currently Fourth Year Medical Student, Johns Hopkins University School of
	Medicine, Baltimore, MD. Received Excellence in Medical Student Research Award (OR11, 12, 26)
2014	Scott M Lee, Currently a MD candidate at Baylor University, TX (OR22, 28, CR 6)
2014	Steven K Lee, currently a MD candidate at Columbia University, NY (OR24, 26)
2017	Qiuyu Jin, Currently an internal medicine resident at Mayo Clinic, Minnesota (RA 7, CR 11)
2018	Pranay Damera, currently a senior in BS Biology at University of Maryland, College Park, MD (CR 8)

Rishma Gattu, currently undergraduate student at Nova South Eastern University, Fort Lauderdale, FL (OR 41)

#### **Post-doctoral Advisees / Mentees**

2004	Abraham Thomas, Southwest Nephrology Associated, Chicago, IL. Currently Assistant Professor of
	Medicine, Univ Illinois Sch Medicine, Chicago, IL. Advisor for award winning MPH Capstone Project.
	(OR 2)
2009	Shyam Parkhie, nephrology practice, Chief, Exempla St Joseph's Hospital. Denver, CO. (OR 8)
2010	John Havill. Currently private nephrology practice, Las Vegas NV (OR 7, 15, 27)
2011	Purva Sharma. Currently Assistant Professor, Donald and Barbara Zucker School of Medicine at
	Hofstra/Northwell. (CR4)
2012	Carla Ellis, Received Young Investigator Award by the Renal Pathology Society. Currently Assistant
	Professor of Pathology, Emory University, Atlanta, GA. (OR 15)
2012	Megha Shah, Currently Hospitalist, Franciscan Health System, Tacoma, WA. (CR 5)
2013	Homa Timlin, Currently Assistant Professor of Medicine, Division of Rheumatology, Johns Hopkins
	University SOM (OR 22, 30, 40. CR 9, 10)
2014	Shivani Shah, currently Nephrologist, DuPage Medical Group, Naperville, Illinois (OR 24.27, 28, 29,
	CR 7, RA 6)
2017	Sam Kant, currently nephrology fellow, Johns Hopkins University School of Medicine, Baltimore, MD
	(OR 35, 37, 41, 42, 45, RA 8)

Thesis Committees: None

## **Educational Program Building / Leadership**

2005-Present

Johns Hopkins Vasculitis Center Renal Clinic: Lead Nephrologist focused on diagnosis and management of renal vasculitis and management of vasculitis patients with end stage renal disease and transplant. Nephrology fellows rotate in their second year to gain experience in management of renal vasculitis. I have had four renal fellows, one rheumatology fellow and one pathology fellow who I have mentored and have developed special interest in renal vasculitis leading to research in vasculitis that has been presented in past national society meetings and this year at the American Society of Nephrology Meeting

Educational Demonstration Activities to external audiences, on or off campus: None

## RESEARCH ACTIVITIES

## **Research Focus**

I am a clinical nephrologist and have been evaluating vasculitis patients with renal disease at the Johns Hopkins Vasculitis Center since 2005. My research interests include the assessment of disease activity and long term outcomes of patients with ANCA-associated vasculitis with kidney involvement and improving their treatment. I started a vasculitis center database in 2015. Johns Hopkins Vasculitis Center cohort includes 276 patients, majority of who have renal vasculitis. Disease activity, clinical outcomes and urine samples have been collected prospectively over a median follow-up of 30 month. We have several short and long-term research questions that we plan to address as we expand database enrollment. I have been the P.I. of a multicenter study looking at outcomes of kidney transplant patients with AAV. I have been a co-investigator in the Rituximab versus Cyclophosphamide ANCA associated vasculitis (RAVE trial). We have looked at outcomes of patients with renal involvement in this trial and the manuscript is published in the Journal of the American Society of Nephrology. I was the principal investigator in post hoc analysis of RAVE trial characterizing the inflammatory infiltrates in renal biopsies of patients enrolled in the RAVE trial and correlating with outcome and the corresponding manuscript was published in the American Journal of Nephrology. I am currently the principal investigator for ADVOCATE clinical trial looking at use of complement inhibitor for remission induction in ANCA associated vasculitis. In 2018, I studied urinary mRNA cell expression profiles in patients with ANCA-associated GN to discern disease activity; the findings were presented in ASN Kidney

week 2018. My current research is focused on characterization of Granzyme B producing auto-reactive T cells in renal ANCA-associated Vasculitis

## Research Program Building / Leadership

I am the principal investigator for the longitudinal Johns Hopkins vasculitis center database which collects clinical information and has bio-banked specimens. I have collaborated with faculty at Hopkins and national and international vasculitis experts in observational studies and participated in landmark multi-center clinical trials. I was a co-investigator in the RAVE trial which led to FDA approval of rituximab for treatment of ANCA associated vasculitis and was a co-author in several publications from this trial in top tier journals and lead author for 2 manuscripts which focused on renal cohort. Utilizing her large cohort of patients followed in the Vasculitis Center, and while mentoring fellows conducting research in these diseases, I have reported additional key findings in patients with renal vasculitides. All of these findings were published in top tier nephrology or rheumatology journals. I am currently the site principal investigator for ADVOCATE, a phase 3 trial of novel complement blocker for induction therapy in ANCA vasculitis.

Research Demonstration Activities to external audience, on or off campus None

Inventions, Patents, Copyrights None

**Technology Transfer Activities None** 

## SYSTEM INNOVATION AND QUALITY IMPROVEMENT ACTIVITIES

#### **System Innovation Focus**

Quality Improvement Activities/outside JHMI: Medical Director of Fresenius Kidney Care, Fleet Street, Baltimore. As medical director, my responsibilities include safe, high quality and efficient delivery of renal replacement therapy. The Fleet Street dialysis unit has been consistently top rated among the dialysis units in Baltimore and has always exceeded national ranking for providing high quality dialysis care.

## System Innovation and Quality Improvement efforts within JHMI

With my combined interest in renal transplantation and renal vasculitis, I focused on improving outcomes of patients with end stage renal disease due to renal vasculitis. Renal transplantation has been shown to improve patient survival and quality of life in patients with end stage renal disease. Patients with renal vasculitis and end stage renal disease are not referred for renal transplantation because most community nephrologists feel that vasculitis patients are medically complicated due to the multi system involvement of the vasculitis and fear of relapse of vasculitis in the renal transplant. My protocol for providing medical clearance for these patients for transplant has been successful in increasing the number of transplanted vasculitis patients. Majority of these patients have received pre-emptive renal transplant and are doing well with excellent function of their renal transplant and control of vasculitis. I have published outcomes of these patients in major transplantation journals.

System Innovation and Quality Improvement efforts outside of JHMI None

System Innovation and Quality Improvement Program Building / Leadership None

#### **ORGANIZATIONAL ACTIVITIES**

## **Institutional Administrative Appointments**

1995 Member of Medical Residents Clinic Education Committee York Hospital, York, PA

1995 Member of Utilization and Review Committee. York Hospital, York, PA

2005-2009 Medical Director, DaVita White Square Dialysis 2009-06/2016 Medical Director, DaVita JB Zachary Triad Dialysis

2010-Present Member of Pharmacy and Therapeutics Committee. Johns Hopkins Bayview Medical Center.

2010-06/2016 Medical Director, DaVita White Square Peritoneal Dialysis

2014-Present Faculty for Medical School Admission Committee
2014-Present Associate Director, Johns Hopkins Vasculitis Center

06/2016-Present Medical Director, Fresenius Kidney Care, Fleet Street, Baltimore, Maryland.

12/2016 Handler Chair Search Committee Member 09/2018 Nephrology faculty search committee 11/2019 Nephrology faculty search committee

#### **Editorial Activities**

#### **Editorial Board Appointments**

2011-06/2017 The Scientific World Journal

2014-Present International Journal of Nephrology and Kidney Failure

2015-Present Journal of Vasculitis

## Journal peer review activities

2005-Present Journal of American Society of Nephrology

2006-Present Medicine

2009-Present American Journal of Transplantation

2011-Present Clinical Nephrology

2012-Present Seminars in Arthritis and Rheumatism

2013-Present Transplantation

2013-Present Journal of Rheumatology 2013-Present Transplant International

2013- Present Nephrology Dialysis and Transplantation

2015-Present Annals of Internal Medicine 2015-Present Arthritis Care and Research

2016-Present Kidney International

2016-Present Clinical Journal of the American Society of Nephrology

2018-Present Kidney International Reports
2018-Present Nature Scientific reports
2018-Present Arthritis and Rheumatology

## Advisory Committees, Review Groups/Study Sections

1996 Represented York Hospital for Medical Jeopardy at the Regional ACP meeting. Valley Forge, PA

1998-Present Member of Medical Advisory Board of National Kidney Foundation Maryland Chapter 2001-Present Invited Relevance reviewer for Nephrology certification and recertification examination

2005-Present Member of NephSAP Review Panel for American Society of Nephrology
2009 Invited Abstract Reviewer for American Transplant Congress 2010
2010 Invited Abstract Reviewer for American Transplant Congress 2011
2010 Faculty Preceptor for medical students and residents for ASN 2010
2011 Medical Director: KEY Screening, National Kidney Foundation

2011 Member of American Society of Transplantation Women's Health Community of Practice

2011 Invited Abstract Reviewer for American Transplant Congress 2012

2011 Grant Reviewer, National Kidney Foundation of Maryland

#### **CONFIDENTIAL**

2012	Invited Co-chair for the abstract review committee on the topic of Clinical: Kidney-Polyoma for American Transplant congress 2013
2012-Present	Early Career Reviewer at the Center for Scientific Review, National Institute of Health
2013	Grant Reviewer, National Kidney Foundation of Maryland
2013	Abstract judge for 2014 Medical Student Research Day at Johns Hopkins University
2014	Invited faculty for ASN strategic planning listening session
2014	Abstract judge for 2015 Medical Student Research Day at Johns Hopkins University
2015-2018	Member of the American Society of Nephrology Post Graduate Education Committee
2015	Abstract judge for 2016 Medical Student Research Day at Johns Hopkins University
2016	Invited Co-Chair, ASN Kidney Week session: ANCA associated Vasculitis: An evolving disease
2016-Present	Member of Diagnostic and Classification Criteria in Vasculitis (DCVAS) review panel
2017	Invited Grant Reviewer Kidney Research U.K
2017-Present	ASN Kidney health initiative representative for Vasculitis Foundation
2017-Present	IgA vasculitis study group member
2017-Present	BVAS/VDI Adjudication committee member, ADVOCATE trial, ANCA associated vasculitis
2017	Invited Co-Chair for ASN Kidney Week 2017 session: Challenges in Glomerular disease
	management: Where an expert opinion counts
2018	Peer review panel: European Medical Journal Nephrology
2018	Work group member: Surrogate End-points in FSGS: ASN Kidney Health Initiative Project
2018	Invited Abstract Reviewer for ASN Kidney Week 2018
2018	Invited Abstract Reviewer for late breaking clinical trials ASN Kidney Week 2018
2018	Member of the planning committee for the 7 <sup>th</sup> Annual American Society of Nephrology Kidney
2010	Health Initiative Annual Stakeholders meeting
2018	Vasculitis Foundation Grant review member
2018	Invited participant for the OMERACT Glucocorticoid Impact Delphi study
2019	Panel member for Question and Answer session on renal vasculitis. Cutting Edge vasculitis: 19 <sup>th</sup>
2010	International Vasculitis and ANCA workshop, Philadelphia, April 2019
2019	Invited Co-Chair for ASN Kidney Week 2019 session: Clinical trials in Glomerular disease:
2010	Famine to Feast
2019	Invited Chair for ASN Kidney Week 2019: Trainee case reports  Member of ASN mid-career award selection subcommittee
2020	
2020	American Society of Nephrology Kidney week 2020 abstract reviewer for section on glomerular
2020	diseases  Invited collaborator to develop response criterio for ANCA associated vecestific for year in clinical.
2020	Invited collaborator to develop response criteria for ANCA associated vasculitis for use in clinical trials: joint project by the American College of Rheumatology and European League against
	Rheumatism
	Miculiausiii

## **Professional Societies**

1998-2007	International Society of Nephrology
1998-Present	American Society of Nephrology
2000-2016	American Society of Transplantation
2016 to Present	American College of Rheumatology

## **Conference Organizer**

2021 International Scientific Committee member, International Vasculitis and ANCA workshop:

Dublin, Ireland

**Session Chair** 

2006 Strategies for dialysis and transplant in patients with ESRD and vasculitis. Break out session for

International Vasculitis Foundation Patient Symposium. Baltimore, Maryland, U.S.A.

2013 American Transplant Congress: Clinical Polyoma session Chair, Seattle, Washington, U.S.A.

Consultantships

04/2017-Present ChemoCentryx: BVAS/VDI adjudicator for ADVOCATE study

## RECOGNITION

### Awards, Honors

2010 Inducted to Miller Coulson Academy of Clinical Excellence. The Miller-Coulson Academy of Clinical Excellence (MCACE) is an initiative sponsored by the Center for Innovative Medicine and was created with a mission to recognize masterful physicians who are steadfastly committed to clinical excellence for the benefit of the patients and communities that they serve. The Academy employs a rigorous process to successfully identify exceptional clinicians. MCACE's clinical portfolio, the tool that was developed to assess clinical accomplishment among faculty members undergoing consideration for membership, is scored by an external review committee of acclaimed leaders in patient care from top academic medical centers 2010 Fellow of American Society of Nephrology (FASN) 2011 Medical Consultant - Vasculitis Foundation. The Vasculitis Foundation is an International organization for patients with vasculitis, their family, friends and health care providers who care for them. The vasculitis foundation medical consultants are recognized authorities in the medical community Early Career Reviewer at the Center for Scientific Review, National Institute of Health 2012 Golden Heart Award from Johns Hopkins Bayview Medical Center for Patient Care 2017 2018 Johns Hopkins Leadership Program for Women Faculty participant 2019 American Society of Nephrology Distinguished Clinical Service Award

#### **Invited Talks**

JHMI/Regional	
2000	"Renophobia Relief" CME course. "Drugs and Kidney: Practical Bedside Pharmacology,
	Baltimore Maryland
2001	Polyomavirus Nephropathy. Grand Rounds. Johns Hopkins Bayview . Baltimore, MD
2002	Acute interstitial nephritis. Grand Rounds. Johns Hopkins Bayview. Baltimore, MD
2003	"HIV and ESRD: ESRD Conference
	Division of Nephrology, Johns Hopkins Bayview Medical Center, Baltimore, Maryland
2004	"ABC of Renal Transplantation" BK virus infection in Kidney Transplant Patients, Baltimore, MD
2004	"Treatment of Membranous Nephropathy": Topics in Nephrology
	Division of Nephrology, Johns Hopkins Bayview Medical Center, Baltimore, Maryland
2006	Polyomavirus nephropathy in renal transplant recipients. Renal Grand Rounds. Johns Hopkins
	University, School of Medicine. Baltimore, Maryland.
2006	"Proteomics in Nephrology": Topics in Nephrology
	Division of Nephrology, Johns Hopkins Bayview Medical Center, Baltimore, Maryland
2007	Treatment approaches to ANCA associated vasculitis. Renal Grand Rounds. Johns Hopkins
	University School of Medicine. Baltimore, Maryland.
2011	What should a Rheumatologist know about renal vasculitis? Rheumatology Grand Rounds. Johns
	Hopkins University School of Medicine. Baltimore, Maryland.
2011	What should a Nephrologist know about ANCA vasculitis? Renal Grand Rounds. Johns Hopkins
	University School of Medicine. Baltimore, Maryland
2013	Advances in therapy of ANCA associated renal disease: Medical Grand Rounds: Johns Hopkins
	Hospital, Johns Hopkins University School of Medicine, Baltimore, Maryland
2016	ANCA associated vasculitis: update on diagnosis and management. Medical Grand Rounds: St.
	Agnes Hospital, Baltimore, Maryland
2016	Approach to relapse prevention in ANCA associated vasculitis. Renal Rounds: University of
	Maryland Medical Center, Baltimore, Maryland
2017	ANCA associated vasculitis: update on diagnosis and management. Medical Grand Rounds:
	Greater Baltimore Medical Center, Baltimore, Maryland
2017	Recognition and management of kidney disease: 2017 Vasculitis foundation regional conference,
	Bethesda North Marriott Hotel, Bethesda, Maryland

## CONFIDENTIAL

National	
2012	Novel Therapies for Vasculitis Associated Renal Disease: National Kidney Foundation Spring Clinical Meeting 2013, Orlando, FL
2013	Granulomatosis with polyangiitis and microscopic polyangiitis: Breakout session speaker, International Vasculitis Patient Symposium, Philadelphia PA
2013	Kidney involvement in vasculitis: Breakout session speaker, International Vasculitis Patient Symposium, Philadelphia PA
2017	Kidney involvement in vasculitis: 2017 International Vasculitis Symposium, Chicago, IL
2017	Rapidly Progressive Glomerulonephritis: 2017 Autoimmune Symposium Rare diseases La Jolla Institute, San Diego, CA
2017	Retiform Purpura and Pauci-immune Glomerulonephritis: Clues to the Culprit. ASN Kidney Week 2017, New Orleans LA
2018	Management of ANCA associated vasculitis: Glomerular disease update: ASN Kidney Week Early Program, San Diego, CA
2018	Tailoring maintenance therapy in ANCA vasculitis. ASN Kidney Week 2018, San Diego CA
2019	Vasculitis and renal transplantation. Cutting Edge Vasculitis. 19 <sup>th</sup> International Vasculitis and ANCA workshop, Philadelphia, April 2019
2019	Management of ANCA associated vasculitis: Glomerular disease update: ASN Kidney Week Early Program, Washington DC
2019	Pathogenesis and prognosis of ANCA associated vasculitis. Kidney Disease Improving Global Outcome (KDIGO) Clinical Practice Conference, Alexandra, VA
2020	Targeting complement in patients with ANCA associated vasculitis, ASN 2020 Kidney Week
International	
2018	ANCA associated vasculitis: Advances in induction therapy: Renal Grand rounds and meet the professor: Stanley Medical College, Chennai, India. 1/10/18
2020	"(How) should we alter acute management of AAV in the COVID-19 era?" UKIVAS and Royal Society of Medicine virtual meeting: scheduled date November 11 <sup>th</sup> to 12 <sup>th</sup> 2020